Type 2 Diabetes
Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C InfectionNovember 15, 2018
The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N = 17,848) to untreated HCV patients with follow-up data (N = 108,350).
Dapagliflozin was not associated with either a higher or lower rate of MACE compared with placebo in patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease.
High circulating total prolactin concentrations may be linked with a lower risk for type 2 diabetes in women.
The American Diabetes Association issued a position statement outlining the recognition, management, and prevention of T2D in the pediatric population.
Patients with diabetes and depressive symptoms who received community-based peer support for diabetes management reported less frequent acute care visits and hospitalizations than patients with diabetes without depressive symptoms.
Approximately 50% of deaths in people with type 2 diabetes worldwide, and approximately two-thirds of deaths in people with type 2 diabetes in the US are caused by cardiovascular disease.
Postprandial hypoglycemia may occur after Roux-en-Y gastric bypass in patients with type 2 diabetes, independent from diabetes remission.
Hypoglycemia was associated with early and late prothrombotic changes in the ﬁbrin network in individuals with type 2 diabetes.
Dapaglifozin and vildagliptin impact cardio-metabolic processes differently.
Diabetic complications were more prevalent in patients with both sickle-cell trait and T2D than in patients with T2D alone.
The ADA and the AHA launch a long-term awareness and education initiative for the prevention of deaths due to cardiovascular complications in patients with T2D.
Patients who have the entire or left side of the colon removed show increased risk for developing type 2 diabetes in the 18 years following surgery.
Patients with both Parkinson disease and type 2 diabetes were more likely to have cardiovascular comorbidities than those with only Parkinson disease.
For adults with type 2 diabetes, plant-based diets can improve psychological health, quality of life, hemoglobin A1c levels, and weight.
Early detection of lipidome characteristics could help identify the early onset of type 2 diabetes.
In recognition of National Diabetes Education Week, Endocrinology Advisor compiled a list of resources to assist clinicians when educating patients with diabetes about their condition.
Intensive BP control and fenofibrate use in patients with T2D who are at high risk for CVD may increase the risk for adverse kidney events.
Access to ready-to-eat outlets that sell food for instant consumption is associated with greater risk for type 2 diabetes.
The impurity was identified following laboratory testing conducted by the Food and Drug Administration (FDA); this is the first non-valsartan product that the Agency has found to contain NDEA.
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
Hyperglycemia, obesity, and hypertriglyceridemia in type 2 diabetes are negatively related to indices of cardiovascular autonomic neuropathy.
The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.
Compared with women who experience normal or late menopause, women who experience early natural menopause have a shorter life expectancy and spend fewer years without type 2 diabetes.
Type 2 diabetes is an independent risk factor for sudden cardiac arrest and death in patients with coronary artery disease with preserved ejection fraction.
LY3298176, a dual GIP and GLP-1 receptor agonist, showed significantly better efficacy than dulaglutide with regard to glucose control and weight loss in type 2 diabetes.
Gastric banding and metformin resulted in similar improvements in insulin sensitivity in moderately obese adults with impaired glucose tolerance or mild T2D over a 2-year period.
Researchers found that higher levels of fatty acid biomarkers 15:0, 17:0, and trans-16:1n7 were inversely associated with risk for T2D.
Individuals who develop diabetes or prediabetes have elevated fasting plasma glucose (FPG) at least 10 years before diagnosis.
There was not a clinically relevant association between DPP-4 inhibitors or GLP-1 receptor agonists and depression or self-harm in type 2 diabetes.
Researchers analyzed how improvements in metabolic syndrome may impact the risk of developing type 2 diabetes and cardiovascular disease in patients with prediabetes.
Endocrinology Advisor Articles
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Measuring Time in Range During CGM May Be Useful Outcome Metric for Clinical Trials
- HbA1c Variability in General Population Increases Risk for Cardiovascular Events, All-Cause Mortality
- Safety and Effectiveness of the Most Common Bariatric Procedures Examined
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D
- High Circulating Prolactin Concentrations May Lower Risk for Type 2 Diabetes
- Online Tool Helps Patients With Advance Care Planning
- Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
- Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C Infection
- Technological Breakthroughs in Medicine Move Physician-Patient Interactions From The Computer Screen Back to the Exam Room